Lightcast raised $27 million to commercialize its Envisia platform for massively parallel droplet-based single-cell functional assays. The Cambridge, UK-based company plans to use the capital to scale operations and advance product deployment. The Envisia approach targets a key limitation of many single-cell workflows by moving beyond profiling to functional readouts at scale. For drug discovery and translational biology, this positions the company to support higher-throughput screening of cellular responses that may correlate better with therapeutic mechanism. The financing highlights continued investor appetite for assay platforms that can translate complex biology into usable datasets for pharmaceutical R&D.